Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2021, Vol. 26 ›› Issue (2): 223-229.doi: 10.12092/j.issn.1009-2501.2021.02.015

Previous Articles     Next Articles

Research progress of thyroid dysfunctions during treatment with immune-checkpoint inhibitors

MIN Hang1,2, GUO Mengran1,2, YE Yue1,2, XU Xiaoshuang1,2, ZHEN Donghu2   

  1. 1 The First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu, China; 2 Department of Endocrinology, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China
  • Received:2020-09-10 Revised:2021-01-03 Online:2021-02-26 Published:2021-03-04

PDF (PC)

252

Abstract: Thyroid dysfunction (TD) is one of the commonest endocrine immunotherapy-related adverse events (IRAEs) during cancer patients' treatment with immune checkpoint inhibitors (ICIs). In the hope that cooperation between departments will be enhanced to alleviate the side effect of immunotherapy which thyroid dysfunctions can cause, this review is contributed to make more endocrinologists and oncologists acknowledge and master clinical characteristics, diagnostic methods and therapeutic strategies of thyroid IRAEs, by the introduction of its pathogenesis, epidemiological features, diagnosis, treatment and prognosis.

Key words: thyroid dysfunction (TD),  immunotherapy-related adverse events (IRAEs), immune checkpoint inhibitors (ICIs)

CLC Number: